173 related articles for article (PubMed ID: 37743467)
1. Synergistic effect of YOD1 and USP21 on the Hippo signaling pathway.
Park SS; Baek KH
Cancer Cell Int; 2023 Sep; 23(1):209. PubMed ID: 37743467
[TBL] [Abstract][Full Text] [Related]
2. YOD1 Deubiquitinates NEDD4 Involved in the Hippo Signaling Pathway.
Park JH; Kim SY; Cho HJ; Lee SY; Baek KH
Cell Physiol Biochem; 2020 Jan; 54(1):1-14. PubMed ID: 31916733
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating enzyme YOD1 deubiquitinates and destabilizes α-synuclein.
Park SS; Do HA; Park HB; Choi HS; Baek KH
Biochem Biophys Res Commun; 2023 Feb; 645():124-131. PubMed ID: 36682332
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability.
Kim Y; Kim W; Song Y; Kim JR; Cho K; Moon H; Ro SW; Seo E; Ryu YM; Myung SJ; Jho EH
Proc Natl Acad Sci U S A; 2017 May; 114(18):4691-4696. PubMed ID: 28416659
[TBL] [Abstract][Full Text] [Related]
5. USP21 regulates Hippo pathway activity by mediating MARK protein turnover.
Nguyen HT; Kugler JM; Loya AC; Cohen SM
Oncotarget; 2017 Sep; 8(38):64095-64105. PubMed ID: 28969054
[TBL] [Abstract][Full Text] [Related]
6. USP21 regulates Hippo signaling to promote radioresistance by deubiquitinating FOXM1 in cervical cancer.
Li Z; Liu X; Yu H; Wang S; Zhao S; Jiang G
Hum Cell; 2022 Jan; 35(1):333-347. PubMed ID: 34825342
[TBL] [Abstract][Full Text] [Related]
7. Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer.
Kim Y; Jho EH
BMB Rep; 2017 Jun; 50(6):281-282. PubMed ID: 28502290
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-specific protease 21 promotes tumorigenicity and stemness of colorectal cancer by deubiquitinating and stabilizing ZEB1.
Lin JJ; Lu YC
World J Gastrointest Oncol; 2024 Mar; 16(3):1006-1018. PubMed ID: 38577450
[TBL] [Abstract][Full Text] [Related]
9. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
10. Neural precursor cell-expressed, developmentally down-regulated 4 (NEDD4) regulates hydrogen peroxide-induced cell proliferation and death through inhibition of Hippo signaling.
Jeon SA; Kim DW; Cho JY
FASEB J; 2019 Dec; 33(12):14772-14783. PubMed ID: 31690112
[TBL] [Abstract][Full Text] [Related]
11. Deubiquitinating Enzyme USP21 Inhibits HIV-1 Replication by Downregulating Tat Expression.
Gao W; Li G; Zhao S; Wang H; Huan C; Zheng B; Jiang C; Zhang W
J Virol; 2021 Jun; 95(13):e0046021. PubMed ID: 33827943
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.
Zhou X; Li Y; Wang W; Wang S; Hou J; Zhang A; Lv B; Gao C; Yan Z; Pang D; Lu K; Ahmad NH; Wang L; Zhu J; Zhang L; Zhuang T; Li X
Theranostics; 2020; 10(21):9443-9457. PubMed ID: 32863938
[No Abstract] [Full Text] [Related]
13. Salt-like transcription factor 4 promotes laryngeal cancer progression through transcriptional activation of ubiquitin-specific protease 21 to stabilize Yin Yang 1.
Wang QD; Liu LL; Li D; Gao L; Zhang MJ
Pathol Int; 2023 Mar; 73(3):109-119. PubMed ID: 36285444
[TBL] [Abstract][Full Text] [Related]
14. Targeting YOD1 by RNA Interference Inhibits Proliferation and Migration of Human Oral Keratinocytes through Transforming Growth Factor-
Zhou XL; Chen G; Li MX; Wang HX; Hong JW; Shen JY; Wang Q; Ge X; Ding Z; Xu LC
Biomed Res Int; 2018; 2018():6254308. PubMed ID: 30345304
[TBL] [Abstract][Full Text] [Related]
15. The USP21/YY1/SNHG16 axis contributes to tumor proliferation, migration, and invasion of non-small-cell lung cancer.
Xu P; Xiao H; Yang Q; Hu R; Jiang L; Bi R; Jiang X; Wang L; Mei J; Ding F; Huang J
Exp Mol Med; 2020 Jan; 52(1):41-55. PubMed ID: 31956270
[TBL] [Abstract][Full Text] [Related]
16. NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation.
Salah Z; Cohen S; Itzhaki E; Aqeilan RI
Cell Cycle; 2013 Dec; 12(24):3817-23. PubMed ID: 24107629
[TBL] [Abstract][Full Text] [Related]
17. USP21 contributes to the aggressiveness of laryngeal cancer cells by deubiquitinating and stabilizing AURKA.
Wang QD; Shi T; Xu Y; Liu Y; Zhang MJ
Kaohsiung J Med Sci; 2023 Apr; 39(4):354-363. PubMed ID: 36919585
[TBL] [Abstract][Full Text] [Related]
18. YOD1 serves as a potential prognostic biomarker for pancreatic cancer.
Zhang Z; Zhao W; Li Y; Li Y; Cheng H; Zheng L; Sun X; Liu H; Shao R
Cancer Cell Int; 2022 May; 22(1):203. PubMed ID: 35642058
[TBL] [Abstract][Full Text] [Related]
19. Blockade of deubiquitinase YOD1 degrades oncogenic PML/RAR
Shao X; Chen Y; Wang W; Du W; Zhang X; Cai M; Bing S; Cao J; Xu X; Yang B; He Q; Ying M
Acta Pharm Sin B; 2022 Apr; 12(4):1856-1870. PubMed ID: 35847510
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the Hippo signaling pathway by ubiquitin modification.
Kim Y; Jho EH
BMB Rep; 2018 Mar; 51(3):143-150. PubMed ID: 29366444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
